Immunic Inc. (NASDAQ:IMUX) went down by -3.76% from its latest closing price compared to the recent 1-year high of $14.50. The company’s stock price has collected 16.23% of gains in the last five trading sessions.
Is It Worth Investing in Immunic Inc. (NASDAQ :IMUX) Right Now?
Plus, the 36-month beta value for IMUX is at 1.65. Opinions of the stock are interesting as 3 analysts out of 4 who provided ratings for Immunic Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $16.50, which is $19.38 above the current price. IMUX currently public float of 36.07M and currently shorts hold a 19.60% ratio of that float. Today, the average trading volume of IMUX was 1.77M shares.
IMUX’s Market Performance
IMUX stocks went up by 16.23% for the week, with a monthly jump of 51.69% and a quarterly performance of -80.54%, while its annual performance rate touched -82.87%. The volatility ratio for the week stands at 11.92% while the volatility levels for the past 30 days are set at 9.02% for Immunic Inc. The simple moving average for the period of the last 20 days is 24.44% for IMUX stocks with a simple moving average of -56.98% for the last 200 days.
Analysts’ Opinion of IMUX
Many brokerage firms have already submitted their reports for IMUX stocks, with SVB Leerink repeating the rating for IMUX by listing it as a “Mkt Perform.” The predicted price for IMUX in the upcoming period, according to SVB Leerink is $5 based on the research report published on October 21st of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $26. The rating they have provided for IMUX stocks is “Buy” according to the report published on September 19th, 2022.
Aegis Capital gave a rating of “Buy” to IMUX, setting the target price at $55 in the report published on April 15th of the previous year.
IMUX Trading at 30.56% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.66% of loss for the given period.
Volatility was left at 9.02%, however, over the last 30 days, the volatility rate increased by 11.92%, as shares surge +42.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.33% upper at present.
During the last 5 trading sessions, IMUX rose by +16.23%, which changed the moving average for the period of 200-days by -85.27% in comparison to the 20-day moving average, which settled at $1.4650. In addition, Immunic Inc. saw 27.86% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at IMUX starting from Neermann Joerg, who purchase 47,000 shares at the price of $1.26 back on Dec 14. After this action, Neermann Joerg now owns 100,000 shares of Immunic Inc., valued at $59,032 using the latest closing price.
Neermann Joerg, the Director of Immunic Inc., purchase 35,000 shares at $1.25 during a trade that took place back on Dec 13, which means that Neermann Joerg is holding 53,000 shares at $43,610 based on the most recent closing price.
Stock Fundamentals for IMUX
Equity return is now at value -67.90, with -62.00 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 9.21.